LXRX ▼ -0.7% - Lexicon Pharmaceuticals, Inc. $LXRX - Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy 23-OCT-2026 08:30 AM ET